Fierce Pharma
AUGUST 7, 2024
The first horse carrying Novartis’ immunoglobulin A nephropathy (IgAN) troika has crossed the FDA finish line. | The first horse carrying Novartis’ immunoglobulin A nephropathy (IgAN) troika has crossed the FDA finish line.
Salesforce
AUGUST 7, 2024
When a customer isn’t happy, businesses tend to scramble and try to turn things around. However, reactive marketing is like a Band-Aid. It might stop the immediate hurt or frustration, but it doesn’t fix the underlying problem. Eventually, the wound could be reopened. The way around this is to build customer loyalty with an “always on” marketing strategy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
AUGUST 7, 2024
Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold. | Novo Nordisk’s attempt to gain an approval to treat heart failure patients with its obesity drug Wegovy has been put on hold. In its quarterly earnings presentation, the Danish company said that after discussions with the FDA, it has pulled its filing and expects to resubmit in early 2025.
MedCity News
AUGUST 7, 2024
Cigna is distributing about $3 million to 22 nonprofits addressing youth mental health. Over the next three years, the company is allocating $9 million total. The post Cigna Distributes Grants to 22 Nonprofits Focused on Youth Mental Health appeared first on MedCity News.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
AUGUST 7, 2024
Amgen’s roller coaster ride known as Tepezza is ascending again. Is the thyroid eye disease (TED) treatment finally gaining momentum that is sustainable? | Amgen’s roller coaster ride known as Tepezza is ascending again. Is the thyroid eye disease (TED) treatment finally gaining momentum that is sustainable? In the second quarter, Tepezza generated $479 million in sales for an increase of 8% year over year and 13% sequentially.
MedCity News
AUGUST 7, 2024
WebMD Ignite recently released new products aimed at helping providers close financial gaps by targeting a specific problem: revenue leakage. The post WebMD’s New Tech Targets Referral Leakage as Providers Continue to Battle Rising Costs appeared first on MedCity News.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
AUGUST 7, 2024
Health plans can reduce late payment interest by up to 25% year over year by focusing on three critical areas. The post The Critical Imperative for Health Plans to Tackle Late Payment Interest appeared first on MedCity News.
Fierce Pharma
AUGUST 7, 2024
In a deal worth approximately $405 million, Danish drugmaker Pharmacosmos has agreed to acquire G1 Therapeutics and the latter company's flagship product Cosela. | The companies will team up to expand the reach of G1's Cosela, which is used to reduce bone marrow damage associated with certain chemotherapy regimens.
MedCity News
AUGUST 7, 2024
G1 Therapeutics turned research from the University of North Carolina at Chapel Hill into novel cancer drug Cosela, which is approved in the U.S. and China. Pharmacosmos says its G1 acquisition will enable Cosela to reach more lung cancer patients around the world. The post Path Forward for Cancer Biotech G1 Therapeutics Is $405M Acquisition by Pharmacosmos appeared first on MedCity News.
Fierce Pharma
AUGUST 7, 2024
In its first full quarter on the market, Madrigal Pharmaceuticals’ Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), achieved sales of $14.6 million. | In its first full quarter on the market, Madrigal Pharmaceuticals’ Rezdiffra, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), achieved sales of $14.6 million.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
AUGUST 7, 2024
BioMarin Pharma has decided not to divest its haemophilia A gene therapy Roctavian but is reining back its ambitions for the business, for now
Fierce Pharma
AUGUST 7, 2024
As multiple drugmakers race to bring novel, levodopa-based Parkinson’s disease treatments to the market, New Jersey’s Amneal has taken home the gold in the U.S. | Late Wednesday, the FDA granted approval to Amneal’s Crexont—formerly known as IPX203—which is an oral, extended-release formulation of the common Parkinson’s disease (PD) drugs carbidopa/levodopa (CD/LD).
pharmaphorum
AUGUST 7, 2024
Weaker sales of obesity drug Wegovy cause a dip in Novo Nordisk's share price, but CEO says volume growth is strong and will accelerate in second half
Fierce Pharma
AUGUST 7, 2024
With supplies of its star obesity med Wegovy now largely unfettered, Novo Nordisk is dialing up its sales expectations for the remainder of the year—and teasing the potential for net price declines | With supplies of its star obesity med Wegovy now largely unfettered, Novo Nordisk is dialing up its sales expectations for the remainder of the year—and teasing the potential for net price declines on the immensely popular GLP-1.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
AUGUST 7, 2024
As many as 25 percent of all ER visits by older adults come from people with dementia. A better alternative is urgent medical response at home – working with seniors in their own familiar place without the pressures, distractions, or costs of a bustling ER. Or the endless wait times. The post Pandemic Lesson: How to Move Healthcare From the Emergency Room to the Living Room appeared first on MedCity News.
Fierce Pharma
AUGUST 7, 2024
Despite a rocky start to the year for Merck KGaA’s contract development and manufacturing group, the German company is finding some reason to be optimistic about its recent performance. | After a rocky start to the year, Merck KGaA’s CDMO and process solutions units appear to be nearing a comeback.
pharmaphorum
AUGUST 7, 2024
A non-opioid drug for pain developed by UK biotech Levicept, with a new mechanism of action, has shown it can reduce pain associated with osteoarthritis in a phase 2 trial.Neurotrophin-3 (NT-3) inhibitor LEVI-04 hit all its primary and secondary objectives in the trial, which enrolled 510 patients with moderate-to-severe osteoarthritis of the knee, raising the hope it could become a non-addictive option for patients needing chronic pain relief.
Pharmaceutical Commerce
AUGUST 7, 2024
Why it is important for organizations to set long-term goals when planning for a sustainable future?
pharmaphorum
AUGUST 7, 2024
Around 14,000 women in England may soon be able to access osteoporosis drug Eladynos from Theramex after NICE backed NHS use
Pharmaceutical Commerce
AUGUST 7, 2024
In an interview with Pharma Commerce Editor Nicholas Saraceno, Michael Rowe, Two Labs’ Sr. Director, DSCSA/Serialization Compliance Services, Two Labs, offers a brief overview of the Drug Supply Chain Security Act.
PM360
AUGUST 7, 2024
In June 2024, the FDA extended a Cooperative Research and Development Agreement (CRADA) to assess data quality in multicenter clinical trials using statistical modeling and ML. François Torche, Chief Product & Technology Officer & Co-Founder at CluePoints dispels the myth that, at least in RBQM, there is such a thing as too much data, and discusses how advanced data analytics platforms are the key to ensuring every data point has a chance to share its story.
PharmaTimes
AUGUST 7, 2024
Researchers aim to explore and investigate axonal dysfunction in neurodegeneration
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
PM360
AUGUST 7, 2024
Pharma Brands Can Take Steps Now to Prepare Intelligence is changing how we access information and the industry behind it. Since Google’s launch, when people needed to ask a question or find information they jumped to a search engine. While we have come a long way from the original 10 blue links, the search industry has not seen such a watershed moment in its lifespan until now.
Pharmaceutical Commerce
AUGUST 7, 2024
The latest news for pharma industry insiders.
pharmaphorum
AUGUST 7, 2024
FDA approves Servier's IDH 1/2 inhibitor vorasidenib as the first targeted therapy for incurable brain cancer glioma
PharmaTimes
AUGUST 7, 2024
Type 1 diabetes accounts for approximately 10% of diabetes cases in the UK
PM360
AUGUST 7, 2024
How to fully exploit data visualization in clinical trials to ensure all valuable insights are unlocked. Data visualization is a hot topic in clinical trials with its potential to increase efficiency, protect participant safety, and guide informed decision-making to deliver the best chances for trial success. However, data visualization is evolving rapidly and is about far more than just moving from lists and spreadsheets to graphs and charts.
PharmaTech
AUGUST 7, 2024
Join this insightful dialogue where we’ll explore advancements in the evolving world of cell and gene therapy analysis with Daniel Galbraith, Chief Scientific Officer of Solvias. Daniel shares insights from the forefront of drug development, including the complexities of development and commercialization, the financial dynamics of new therapies and changing regulatory landscapes.
PM360
AUGUST 7, 2024
Tackling the Tough Questions and Hidden Opportunities for Healthcare Advertisers As the landscape of consumer privacy legislation rapidly evolves, healthcare marketing teams are reassessing their advertising strategies. New laws aimed at safeguarding personal information are transforming how companies interact with consumers and HCPs. For insights into the implications of these legislative changes, we turned to Karin Hayes, SVP Analytics and Insights, OptimizeRx.
Spotio
AUGUST 7, 2024
Who do you sell to? It’s an important question to answer. If you don’t know your target audience like the back of your hand, you won’t close many deals. So take time to learn about your customer base. Where do they live? What industry are they in? What do they struggle with on a daily basis? And how can your company solve this problem for them?
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
281 
Let's personalize your content